2015

AMRI to acquire Aptuit drug development, aseptic manufacturing businesses

Friday, January 9, 2015

Albany Molecular Research (AMRI), a global contract research and manufacturing organization, has acquired the outstanding equity interests of Aptuit‘s Glasgow, U.K., business and has entered into a definitive agreement to acquire Aptuit’s SSCI/West Lafayette, Ind., business, for a total of $60 million, expanding AMRI’s drug product development and aseptic clinical manufacturing capabilities.

[Read More]

Johnson & Johnson begins phase I clinical trial of Ebola vaccine regimen

Thursday, January 8, 2015

Johnson & Johnson has begun a phase I, first-in-human clinical trial of a preventive Ebola vaccine in development at its Janssen Pharmaceutical Companies. The trial is being led by the Oxford Vaccine Group, part of the University of Oxford Department of Pediatrics. Recruitment in the trial is underway, and the first volunteers have received their initial vaccine dose. Enrollment is expected to be completed by the end of January.

[Read More]

23andMe, Genentech partner to analyze genomic data for Parkinson’s

Thursday, January 8, 2015

23andMe, a privately held personal genomics and biotechnology company based in Mountain View, Calif., has inked an agreement with Genentech, a member of the Roche Group, to generate whole genome sequencing data for approximately 3,000 people in 23andMe’s Parkinson’s disease community. The goal of the collaboration is to identify new therapeutic targets for treating Parkinson’s disease.

[Read More]